Thank you, you are now logged in. x

Australians define low disease activity in lupus

comments

Australians define low disease activity in lupus

Australian experts have presented a new definition of low disease activity in SLE.

Measuring low disease activity in SLE was problematic, and although a definition of remission was published in 2007, it was met by less than 2% of patients, said Professor Eric Morand (pictured) and colleagues from Monash University in Melbourne.

“A definition of lupus low disease activity state (LLDAS) could, once validated, be applied as a novel outcome measure in observational and interventional studies,” they said.

A panel of experts from Hong Kong, China, Australia, Philippines, Thailand and Indonesia met to consider which elements should be included in a definition of low disease activity.

An expert consensus then scored each item, and following two Delphi rounds the following five items received unanimous agreement.

1.     SLEDAI-2K <4, with no SLEDAI activity in major organs.

2.     No new features of lupus disease activity compared to previous assessment

3.     SELENA-SLEDAI physician global assessment (PGA, scale 0-3) <1

4.     Current prednisolone (or equivalent) dose <7.5mg daily; and

5.     Well-tolerated standard maintenance doses of immunosuppressive drugs and/or approved biologic agents.

Following 192 patients for an average of just over three years, the researchers found that LLDAS was achieved on at least one occasion by 72% of patients.

Patients who had a cumulative duration of LLDAS greater than 245 days had significantly less accrual of organ damage, the researchers found.

The definition could serve as a treatment target in SLE clinical practice, but larger studies were needed to validate the findings, they concluded.

Pfizer Immunology proudly sponsored Nicola Garret’s attendance at ACR 2013

 

to get Rheumatology Update delivered to your inbox

Browse our newsletter archive

Advertisement

Rheumatology Update on Twitter

­